Meeting Report

Advances in the Use of Targeted Therapies in the Management of Non–Small Cell Lung Cancer

Presented by Heather Wakelee,(1) MD, and Elizabeth S. Waxman,(2) RN, MSN, AOCN®, ANP-BC

1) Stanford University, Stanford Cancer Institute, Stanford, California; 2) The University of Texas MD Anderson Cancer Center, Houston, Texas

Presenters’ disclosures of conflicts of interest are found at the end of this article.


J Adv Pract Oncol 2018;9(3):303–310 | https://doi.org/10.6004/jadpro.2018.9.3.6 | © 2018 Harborside™


  

ABSTRACT

Mutation-targeted therapies have had a major impact on the treatment of NSCLC, even for patients with advanced disease. Methods for detecting mutations, key clinical trials of targeted therapy, and the most common toxicities of EGFR and ALK inhibition were discussed at JADPRO Live.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2018 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.